Jessica Hope Roark

Array ( [id] => 11263299 [patent_doc_number] => 09487586 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Methods for cancer management targeting Co-029' [patent_app_type] => utility [patent_app_number] => 14/691630 [patent_app_country] => US [patent_app_date] => 2015-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 21 [patent_no_of_words] => 18890 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14691630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333270 [patent_doc_number] => 20150218275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'ANTI-CD16 BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/691509 [patent_app_country] => US [patent_app_date] => 2015-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 19444 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14691509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12367395 [patent_doc_number] => 09957333 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-01 [patent_title] => Anti-CEP antibody or fragment thereof [patent_app_type] => utility [patent_app_number] => 14/689948 [patent_app_country] => US [patent_app_date] => 2015-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 20 [patent_no_of_words] => 20432 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 275 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14689948 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371969 [patent_doc_number] => 20180237525 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-08-23 [patent_title] => VISTA Agonist and Methods of Use [patent_app_type] => utility [patent_app_number] => 14/686422 [patent_app_country] => US [patent_app_date] => 2015-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14686422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13371969 [patent_doc_number] => 20180237525 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2018-08-23 [patent_title] => VISTA Agonist and Methods of Use [patent_app_type] => utility [patent_app_number] => 14/686422 [patent_app_country] => US [patent_app_date] => 2015-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14686422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10405120 [patent_doc_number] => 20150290129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-15 [patent_title] => 'METHOD FOR DELIVERY OF IMMUNOMODULATORS TO A PATIENT' [patent_app_type] => utility [patent_app_number] => 14/685573 [patent_app_country] => US [patent_app_date] => 2015-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 5548 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14685573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10317315 [patent_doc_number] => 20150202318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'ABERRANT CELL-RESTRICTED IMMUNOGLOBULINS PROVIDED WITH A TOXIC MOIETY' [patent_app_type] => utility [patent_app_number] => 14/670271 [patent_app_country] => US [patent_app_date] => 2015-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14576 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14670271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12326172 [patent_doc_number] => 09944709 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-17 [patent_title] => CD123 specific chimeric antigen receptors for cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 15/126540 [patent_app_country] => US [patent_app_date] => 2015-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 30683 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15126540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714911 [patent_doc_number] => 20170183410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'HIGHLY-FUNCTIONAL IgG2 BISPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/128831 [patent_app_country] => US [patent_app_date] => 2015-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 9936 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15128831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10430265 [patent_doc_number] => 20150315278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'Anti-Glypican-3 Antibody Having Improved Kinetics in Plasma' [patent_app_type] => utility [patent_app_number] => 14/629967 [patent_app_country] => US [patent_app_date] => 2015-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 32308 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14629967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11722389 [patent_doc_number] => 09695236 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-04 [patent_title] => 'BCR-complex-specific antibodies and methods of using same' [patent_app_type] => utility [patent_app_number] => 14/629841 [patent_app_country] => US [patent_app_date] => 2015-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 31630 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14629841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347568 [patent_doc_number] => 20150232573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'ANTI-EGFR/ANTI-HER2 BISPECIFIC ANTIBODIES WITH ANTI-EGFR DARPINS' [patent_app_type] => utility [patent_app_number] => 14/625296 [patent_app_country] => US [patent_app_date] => 2015-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8251 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14625296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11714908 [patent_doc_number] => 20170183407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'CHIMERIC ANTIGEN RECEPTORS AND METHODS OF MAKING' [patent_app_type] => utility [patent_app_number] => 15/118245 [patent_app_country] => US [patent_app_date] => 2015-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 17160 [patent_no_of_claims] => 88 [patent_no_of_ind_claims] => 60 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15118245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10333280 [patent_doc_number] => 20150218284 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-06 [patent_title] => 'CD27L ANTIGEN BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/618945 [patent_app_country] => US [patent_app_date] => 2015-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 40461 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14618945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11685016 [patent_doc_number] => 09683048 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-20 [patent_title] => 'Antibody molecules to PD-1 and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/604415 [patent_app_country] => US [patent_app_date] => 2015-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 26 [patent_no_of_words] => 89463 [patent_no_of_claims] => 144 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14604415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347559 [patent_doc_number] => 20150232562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'AMINO ACID SEQUENCES DIRECTED AGAINST HER2 AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF CANCERS AND/OR TUMORS' [patent_app_type] => utility [patent_app_number] => 14/592022 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 45 [patent_no_of_words] => 137143 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11816036 [patent_doc_number] => 09719981 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'RAC1 inhibitors for the treatment of alport glomerular disease' [patent_app_type] => utility [patent_app_number] => 14/580680 [patent_app_country] => US [patent_app_date] => 2014-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 35 [patent_no_of_words] => 33360 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14580680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10325769 [patent_doc_number] => 20150210772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-30 [patent_title] => 'METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND AN ANTI-CD20 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 14/574197 [patent_app_country] => US [patent_app_date] => 2014-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 47913 [patent_no_of_claims] => 59 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14574197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10374398 [patent_doc_number] => 20150259405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-17 [patent_title] => 'Production of Motif-Specific and Context-Independent Antibodies Using Peptide Libraries as Antigens' [patent_app_type] => utility [patent_app_number] => 14/573635 [patent_app_country] => US [patent_app_date] => 2014-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 25198 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14573635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10305507 [patent_doc_number] => 20150190506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'COMBINATION THERAPY COMPRISING OX40 BINDING AGONISTS AND PD-1 AXIS BINDING ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 14/574365 [patent_app_country] => US [patent_app_date] => 2014-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 60483 [patent_no_of_claims] => 88 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14574365 [rel_patent_id] =>[rel_patent_doc_number] =>)